Publicacions en què col·labora amb CELSO ARANGO LÓPEZ (16)

2023

  1. Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: The OPTiMiSE study

    Psychological Medicine, Vol. 53, Núm. 8, pp. 3471-3479

  2. Neighborhood Vulnerability and Disability in First Episode of Psychosis: A Multilevel Study

    The Journal of clinical psychiatry, Vol. 84, Núm. 2

2022

  1. Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis

    Schizophrenia, Vol. 8, Núm. 1

  2. The relationship between negative symptoms, social cognition, and social functioning in patients with first episode psychosis

    Journal of Psychiatric Research, Vol. 155, pp. 171-179

2021

  1. How does neighbourhood socio-economic status affect the interrelationships between functioning dimensions in first episode of psychosis? A network analysis approach

    Health and Place, Vol. 69

  2. Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study

    Schizophrenia bulletin, Vol. 47, Núm. 2, pp. 444-455

  3. The interplay between functioning problems and symptoms in first episode of psychosis: An approach from network analysis

    Journal of Psychiatric Research, Vol. 136, pp. 265-273

2020

  1. Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning

    European Neuropsychopharmacology, Vol. 34, pp. 76-86

2019

  1. CIBERSAM: Ten years of collaborative translational research in mental disorders

    Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 1, pp. 1-8

  2. Influence of social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis

    Psychological Medicine

  3. Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain

    Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 2, pp. 92-105

2018

  1. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study

    The Lancet Psychiatry, Vol. 5, Núm. 10, pp. 797-807

2016

  1. Opposite cannabis-cognition associations in psychotic patients depending on family history

    PLoS ONE, Vol. 11, Núm. 8

2015

  1. Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis: The PEPsCog Study

    Schizophrenia Research, Vol. 164, Núm. 1-3, pp. 65-73

2014

  1. Estudio farmacogenético del tratamiento a largo plazo con antipsicóticos de segunda generación y sus efectos adversos metabólicos (Estudio SLiM): justificación, objetivos, diseño y descripción de la muestra

    Revista de Psiquiatria y Salud Mental, Vol. 7, Núm. 4, pp. 166-178

  2. Replication of previous genome-wide association studies of psychiatric diseases in a large schizophrenia case-control sample from Spain

    Schizophrenia Research, Vol. 159, Núm. 1, pp. 107-113